Target intelligence / Profile preview

Nicotinic acetylcholine receptor α3β4 subunit (nAChR α3β4)

Target
nAChR α3β4
Molecular classification
Ion channel, Ligand-gated ion channel, Receptor
01

Overview

The nicotinic acetylcholine receptor α3β4 subunit (nAChR α3β4) is a pentameric ligand-gated ion channel formed by the assembly of α3 and β4 subunits, predominantly expressed in autonomic ganglia and select brain regions involved in reward circuitry and addiction. Upon binding endogenous acetylcholine or exogenous agonists like nicotine, the channel opens to conduct sodium and potassium ions, mediating fast synaptic transmission and modulating both peripheral and central nervous system signaling. The α3β4 nAChR is a validated therapeutic target for addiction, notably nicotine dependence, and is also implicated in neurodegenerative and cardiovascular diseases; numerous agonists, antagonists, and modulators, including selective small molecules such as AT-1001, are under investigation for clinical and research applications. The receptor's structure displays a pentameric arrangement, with high-resolution images revealing ligand binding domains that confer pharmacological selectivity; its physiological, therapeutic, and side effect profile remains a focal point for CNS and autonomic drug development.

Other names
Alpha3beta4 nicotinic receptorGanglion-type nicotinic receptorα3β4 nAChRα3β4 nicotinic acetylcholine receptor
02

Mechanism of action

Agonists induce channel opening to allow cation influx (Na+, K+), depolarizing post- or presynaptic neurons Antagonists block ion channel function, inhibiting neurotransmission Partial agonists modulate channel with lower efficacy Noncompetitive antagonists block function via allosteric or channel pore binding

03

Biological functions

Signal transductionNeurotransmissionModulation of autonomic ganglionic transmissionRegulation of reward pathways
04

Disease associations

Addiction (especially nicotine dependence)Neurodegenerative disease (implicated in Parkinson's, Alzheimer's)Cardiovascular disease (via autonomic regulation)Other CNS disorders
05

Safety considerations

Potential for autonomic dysfunction (blood pressure, heart rate changes)Seizure risk with excessive stimulationOff-target CNS effects, including nausea, dizziness, cognitive changesPotential psychiatric effects (addiction, mood alterations)
06

Interacting drugs

Nicotine (agonist)

16 more in the full profile.

07

Biomarkers

No established, highly specific clinical biomarkers for α3β4 nAChR; general markers may include ganglionic nAChR autoantibodies (explored in rare autonomic failure syndromes), experimental PET ligands in research

Beyond the preview

Go deeper on Nicotinic acetylcholine receptor α3β4 subunit (nAChR α3β4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinic acetylcholine receptor α3β4 subunit (nAChR α3β4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call